BIONOMICS TO PRESENT PRECLINICAL DATA ON BNC105 AT AACR-NCI-EORTC INTERNATIONAL CONFERENCE

- Synergistic relationship seen with BNC105 and checkpoint inhibitors in preclinical models of colorectal cancer
- BNC105 also shown to suppress renal, breast and soft tissue sarcoma tumor growth in combination with evofosfamide (previously known as TH-302), an investigational hypoxia-activated prodrug, in preclinical models

Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system and cancer, today announced that preclinical data from ongoing studies of BNC105, its vascular disrupting agent, will be presented during a poster session at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held 5-9 November 2015 in Boston, MA.

As reported in the abstracts available online, preclinical results from a study of BNC105 in combination with the hypoxia-activated prodrug evofosfamide (previously known as TH-302) demonstrated encouraging synergistic activity in renal and breast cancer models, as indicated by enhanced tumor growth inhibition over monotherapy. In work completed after abstract submission but included in the poster, the combination of BNC105 and evofosfamide also demonstrated additive activity in a model of soft tissue sarcoma.

Evofosfamide is currently being evaluated in two fully recruited Phase 3 trials for the treatment of locally advanced unresectable or metastatic soft tissue sarcoma and locally advanced unresectable or metastatic pancreatic cancer by Threshold Pharmaceuticals and Merck KGaA, Darmstadt, Germany.

Bionomics, Threshold Pharmaceuticals and Merck KGaA, Darmstadt, Germany collaborated on the preclinical evaluations of BNC105 and evofosfamide.

BNC105 was also studied in vivo in combination with antibodies that target PD-1 or CTLA4 in colorectal cancer xenograft models and data showed a synergistic relationship for the combination therapy when looking at inhibition of tumor growth.
Details of the poster presentations are as follows:

**Poster Session B: Therapeutics Agents: Other**

**B174: Complementary activity of the vascular disruption agent BNC105 and the hypoxia-activated prodrug evofosfamide (TH-302) in suppressing the growth of preclinical renal and breast solid tumors**
Saturday, November 7, 2015, 12:30 PM – 3:30 PM
Exhibit Hall C-D

**Poster Session B: Immune Checkpoints**

**B92: Tubulin-targeting agent BNC105 potentiates the efficacy of immune checkpoint inhibitors in preclinical models of colorectal cancer**
Saturday, November 7, 2015, 12:30 PM – 3:30 PM
Exhibit Hall C-D

Poster Presentations will be available at [www.bionomics.com.au](http://www.bionomics.com.au) following conclusion of the session.

**FOR FURTHER INFORMATION PLEASE CONTACT:**

Australia
Monsoon Communications
Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

US
Stern IR, Inc.
Beth Del Giacco
+1 212 362 1200
beth@sternir.com

---

**About Bionomics Limited**

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics’ lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 (\(\alpha_7\)) nicotinic acetylcholine receptor. The Company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 is expected to enter clinical trials in the fourth quarter of 2015. Bionomics has strategic partnerships with Merck & Co. in pain and cognition.


**Factors Affecting Future Performance**

This release contains "forward-looking" statements within the meaning of the United States’ Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics’ drug candidates (including BNC210 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies
performed on our drug candidates and competitors’ drugs and drug candidates may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.